Gadolinium-based contrast agents
Authors:
- 1 March 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 28 (2) , 154-162
Abstract
Purpose of review The hegemony of gadolinium-based contrast agent-induced adverse events stretches beyond those who have renal impairment. ‘Nephrogenic’ systemic fibrosis is a misnomer: gadolinium-based contrast agents are the known trigger for the disease; kidney impairment is a risk factor. Impaired (true) glomerular filtration may be one catalyst for gadolinium-based contrast agent-induced adverse events, but it is increasingly evident that the same cluster of symptoms occurs in patients with normal renal function. Recent findings It has been known for nearly 30 years that gadolinium-based contrast agents distribute and are cleared according to a three compartment model. Single doses of gadolinium-based contrast agents can trigger ‘nephrogenic’ systemic fibrosis in nondialysis dependent patients. Manifestations have occurred years after exposure. Renal insufficiency alone is not an adequate explanation for ‘nephrogenic’ systemic fibrosis, and the continuum of its symptoms with the adverse events reported by patients with normal renal function clearly indicate that the physiologic reactions are largely undefined. Summary Gadolinium-based contrast agents should be used with extreme caution.Keywords
This publication has 29 references indexed in Scilit:
- No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney DiseaseRadiology, 2018
- Centrality of bone marrow in the severity of gadolinium‐based contrast‐induced systemic fibrosisThe FASEB Journal, 2016
- Type of MRI contrast, tissue gadolinium, and fibrosisAmerican Journal of Physiology-Renal Physiology, 2014
- Nephrogenic Systemic FibrosisThe American Journal of Pathology, 2012
- Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aidJournal of the American Academy of Dermatology, 2011
- Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seenCleveland Clinic Journal of Medicine, 2008
- Nephrogenic Systemic FibrosisInvestigative Radiology, 2007
- Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrology Dialysis Transplantation, 2006
- What Nephrogenic Fibrosing Dermopathy Might BeArchives of Dermatology, 2003
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patientsThe Lancet, 2000